🔗 Permalink

Assignee profile:

XIGEN INFLAMMATION LTD.

City:

Limassol

Country:

Cyprus

Published Applications:

Last publication date:

2020-03-26

Patent Grants:

Last grant date:

2022-05-17

Top Inventors for applications by XIGEN INFLAMMATION LTD.

These are the the leading inventors for applications assigned to XIGEN INFLAMMATION LTD.:

Christophe BONNY 10 Lausanne, Switzerland
Jean-Marc Combette 7 Saint-Cergues, France
Catherine Deloche 7 Genf, Switzerland
Catherine DELOCHE 6 Geneva, Switzerland

Claire Abadie 3 Annecy, France

Recent patent applications by XIGEN INFLAMMATION LTD.

XIGEN INFLAMMATION LTD. based in Limassol, CY has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2020-03-26 ✅ Patent 11,331,364 granted on 2022-05-17

US20200093883A1

Human necessities

Use for JNK inhibitor molecules for treatment of various diseases

#2 | 2019-11-07

US20190337988A1

Chemistry; metallurgy

NOVEL TRANSPORTER CONSTRUCTS AND TRANSPORTER CARGO CONJUGATE MOLECULES

#3 | 2019-02-28 ✅ Patent 10,967,038 granted on 2021-04-06

US20190060392A1

Human necessities

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases

#4 | 2017-10-12 ✅ Patent 11,779,628 granted on 2023-10-10

US20170290877A1

Human necessities

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

#5 | 2017-03-02 ✅ Patent 10,596,223 granted on 2020-03-24

US20170056466A1

Human necessities

JNK inhibitor molecules for treatment of various diseases

#6 | 2016-09-15

US20160264630A1

Chemistry; metallurgy

Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway

#7 | 2016-07-14 ✅ Patent 10,624,948 granted on 2020-04-21

US20160199444A1

Human necessities

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

#8 | 2016-03-31

US20160089413A1

Human necessities

USE OF CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY FOR THE TREATMENT OF CHRONIC OR NON-CHRONIC INFLAMMATORY EYE DISEASES

#9 | 2015-09-24 ✅ Patent 9,624,267 granted on 2017-04-18

US20150266923A1

Chemistry; metallurgy

JNK inhibitor molecules

#10 | 2015-09-03 ✅ Patent 9,610,330 granted on 2017-04-04

US20150246099A1

Human necessities

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

#11 | 2014-07-17 ✅ Patent 9,290,538 granted on 2016-03-22

US20140200187A1

Chemistry; metallurgy

Cell-permeable peptide inhibitors of the JNK signal transduction pathway

#12 | 2013-12-19 ✅ Patent 9,150,618 granted on 2015-10-06

US20130337557A1

Chemistry; metallurgy

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases

#13 | 2013-07-04 ✅ Patent 8,981,052 granted on 2015-03-17

US20130172530A1

Chemistry; metallurgy

JNK inhibitor molecules

#14 | 2012-03-08 ✅ Patent 10,023,615 granted on 2018-07-17

US20120058137A1

Chemistry; metallurgy

Efficient transport into white blood cells

#15 | 2011-08-25 ✅ Patent 9,180,159 granted on 2015-11-10

US20110207677A1

Human necessities

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases

#16 | 2011-07-28 ✅ Patent 9,006,185 granted on 2015-04-14

US20110183888A1

Human necessities

Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

#17 | 2009-12-10 ✅ Patent 8,748,395 granted on 2014-06-10

US20090305968A1

Human necessities

Cell-permeable peptide inhibitors of the JNK signal transduction pathway

Also check out Xigen Inflammation Ltd.'s (Limassol, Cyprus) applicant profile with 8 patent applications submitted.

AssigneeID:

71717 ⎘